Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

The US Food and Drug Administration (FDA) on October 7, 2026, approved Novartis' remibrutinib (Rhapsido), an oral, highly selective Bruton tyrosine kinase (BTK) inhibitor, for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines, making it the first therapy approved specifically for the most common form of chronic inducible urticaria (CIndU).1

Supported by the phase 3 RemIND trial, the decision expands a label first granted for chronic spontaneous urticaria (CSU) in September 2025 and makes remibrutinib the only agent indicated for both conditions, which frequently coexist in the same patient.1,4

Taken at 25 mg twice daily, remibrutinib blocks BTK signaling downstream of the high-affinity IgE receptor on mast cells and basophils, halting the degranulation responsible for wheals and itch, and gives dermatologists an on-label option for a population long managed with off-label regimens.2,7

Frequently Asked Questions

What is remibrutinib approved to treat, and how is it dosed?

Remibrutinib is indicated for adults with SD inadequately controlled by H1 antihistamines and for adults with CSU who remain symptomatic despite H1 antihistamine treatment.1,4 Both indications use the same regimen: 25 mg orally twice daily.1,2 No routine laboratory monitoring is required.1

The dual indication carries practical weight. Adam Friedman, MD, professor and chair of dermatology at George Washington University School of Medicine and Health Sciences, estimated in an HCPLive special report roughly 30% of patients with CSU have a concomitant inducible urticaria; David Cotter, MD, PhD, of Las Vegas Dermatology, put the overlap at 30% to 50% in either direction.6 "What's unique here is that you now have 2 disease states that often happen in the same person, and now a drug that has both indications," Friedman said.

Why does an on-label option for SD matter?

Before this approval, SD had no FDA-approved therapy. Clinicians relied on up-dosing second-generation H1 antihistamines—up to 4 times the standard dose—and on off-label use of biologics approved for CSU, such as omalizumab and dupilumab, for which inducible urticaria evidence is limited.6 Cotter noted dupilumab missed its end points in some CIndU studies.6 Raj Chovatiya, MD, PhD, of Rosalind Franklin University Chicago Medical School, described the approval as providing an on-label option for a population largely treated off-label.7

Friedman framed the significance on 2 levels. For patients: "That approval is a spotlight. It is a giant flag to those suffering that they're seen." For clinicians, phase 3 evidence replaces anecdote: "Having an FDA approval gives us the confidence and the data to be able to realistically predict" response in a typical patient.

How does SD present, and how should clinicians identify it?

SD rarely arrives as a chief complaint. Patients often describe a rash gone by the time of the visit, and the finding is sometimes picked up incidentally—for example, during a skin cancer screening, when a patient rubs an arm and a wheal appears within about 30 seconds. All urticarias resolve within 24 hours by definition, but inducible lesions typically clear within minutes. "It's fast on, fast off," Friedman said.

Bedside provocation remains the diagnostic workhorse. Friedman strokes a tic-tac-toe pattern and waits 30 seconds to 1 minute for wheal and flare; Cotter uses the back of a cotton swab on the forearm.6 Because patients with 1 inducible urticaria often have others and rarely connect them, both experts recommend asking about cold, heat, aquagenic, vibratory, and cholinergic triggers—the latter often presenting as itch or burning after exercise as the body cools. Cotter screens for cold urticaria with an ice cube in a plastic bag when formal threshold testing is unavailable.6 Friedman also cautioned clinicians to correct the common patient misconception of urticaria as an allergic reaction to an external trigger.

What is the mechanism of action?

In CSU, mast cell activation runs through the high-affinity IgE receptor (FcεRI). In type I (autoallergic) disease, IgE bound to an autoallergen cross-links 2 receptors; in type IIb (autoimmune) disease, IgG autoantibodies either cross-link receptor-bound IgE or bind the receptor directly. In each case, BTK relays the signal from the cell surface to the intracellular cascade ending in degranulation and release of histamine and other proinflammatory mediators. "By blocking BTK in a mast cell, it doesn't matter if it's IgE mediated or IgG mediated. It will stop the degranulation of the mast cell," Friedman said.

The pathophysiology of SD is less well defined. According to Friedman, remibrutinib's efficacy in RemIND indicates inducible urticarias also rely on BTK as part of downstream mast cell signaling, offering insight into a mechanism previously poorly understood.

What was the design of the pivotal RemIND trial?

RemIND (NCT05976243) is a 52-week, multicenter, randomized, double-blind, placebo-controlled phase 3 trial.1 The SD cohort enrolled 115 adults with SD for at least 4 months despite H1 antihistamines, randomized 1:1 to remibrutinib 25 mg or placebo twice daily for 24 weeks, followed by a 28-week open-label period on remibrutinib.1 The primary end point was complete response on the Total Fric Score (TFS = 0), a standardized provocation measure, at week 12.1

Mean participant age was 39.2 years, 71.3% were female, 58.3% had a baseline TFS of 4, and mean disease duration was 5.8 years.1 Friedman noted the cohort reinforced clinical impressions: chronic urticarias predominantly affect women and middle-aged adults, and inducible forms tend to persist longer than CSU, which burns out after about 5 years on average.

What were the efficacy findings?

At week 12, 29.3% (17/58) of patients receiving remibrutinib achieved a complete TFS response vs 14.0% (8/57) receiving placebo (treatment difference, 15.0%; 95% CI, 0.3%-29.7%; P = .0229).1,5 All primary and secondary end points reached statistical significance.1

Friedman urged clinicians to read the response rate in context. A complete response means no reaction at all to a rigorous, standardized provocation, and any residual urtication—even without clinical impact—counts as failure on this measure. Given how easily patients with dermographism urticate, he called 30% of patients with no response "very meaningful," noting the condition can shape occupation, social activities, and clothing choices. Cotter pointed to the placebo rate, observed in patients on background antihistamines, as evidence of how poorly antihistamines control SD.6

How quickly does remibrutinib work, and is the response durable?

Separation from placebo emerged by week 2, when 29.3% of the remibrutinib group had a complete TFS response vs 8.8% receiving placebo.1 Itch numerical rating scale scores fell by a least squares mean of 4.0 points at week 2 vs 1.8 points with placebo.1 Response held through week 24 (32.8% vs 15.8%), and results were consistent regardless of baseline total IgE.1

"There's a need for speed," Friedman said, describing patients with years of uncontrolled disease who live waiting for the next flare. Durability carries particular weight in CIndU, he added, because the disease rarely remits; patients need confidence the drug will keep working. Although baseline IgE can predict omalizumab response in CSU, Friedman considered the IgE-independent findings most valuable for generalizability.

What are the most common adverse effects?

Safety in the SD population was consistent with data from the CSU program.1 The most common adverse reactions in pooled CSU trials were nasopharyngitis (11%), bleeding (9%), headache (7%), nausea (3%), and abdominal pain (3%); no severe bleeding events were reported.1,3

Friedman emphasized the value of no routine laboratory monitoring, citing a "hassle effect" in which baseline and follow-up labs reduce both patient adherence and clinician buy-in. He also distinguished remibrutinib from earlier oncology BTK inhibitors, which carried broader adverse effect profiles: "This is not this BTK anymore," he said, attributing remibrutinib's favorable profile to its high selectivity.

What should clinicians counsel patients about bleeding and other label precautions?

Friedman recommended anticipatory counseling on mucocutaneous bleeding. BTK supports platelet function but not platelet formation, and alternative signaling pathways compensate over time. In his practice, petechiae or bruising—particularly among patients in contact sports or physically demanding jobs—have appeared around weeks 6 to 7. "This is not a rate limiter," he said, noting the events have not led to discontinuation. Preparing patients in advance helps; some notice nothing, while others mistake preexisting cherry angiomas for petechiae.

Labeling advises interrupting remibrutinib 3 to 7 days before and after surgery, avoiding live or live-attenuated vaccines, avoiding concomitant strong or moderate CYP3A4 inhibitors and inducers, and avoiding use in patients with hepatic impairment.1,2 Friedman clarified the hepatic precaution concerns impairment severe enough to affect bleeding times, assessed by Child-Pugh classification rather than transaminase levels, and seldom arises when screening otherwise healthy patients.

Where does remibrutinib fit in the treatment algorithm?

For patients with SD or CSU not controlled by antihistamines, both experts see remibrutinib as a central option. Cotter said, "Now that we have an FDA-approved therapy, there is no reason not to use remibrutinib for patients with SD," and reported his omalizumab-experienced CSU patients typically transition to remibrutinib.6 For patients with atopic dermatitis on dupilumab whose SD persists, he would add remibrutinib, although the combination has not been studied.6

Friedman stressed shared decision-making. Twice-daily oral dosing aligns with the routine of patients already taking antihistamines correctly, but some patients prefer the "out of sight, out of mind" convenience of a less frequently dosed injectable. Off-label options remain part of the conversation, he said, but the FDA indication will now anchor it. Both experts cautioned against sorting patients strictly into CSU or CIndU, since a brief history often reveals both.6

What is next for remibrutinib?

Novartis plans to submit RemIND data on cold and cholinergic urticaria to regulators globally.1 Friedman highlighted the unmet need: cold urticaria can be disabling and occasionally dangerous—a plunge into cold water can trigger massive histamine release with systemic consequences—and cholinergic urticaria can limit exercise and heat-exposed occupations. He also hopes to see work in mast cell activation syndrome and other mast cell diseases.

Beyond urticaria, remibrutinib is under study in hidradenitis suppurativa and food allergy, and phase 3 REMODEL-1 and REMODEL-2 trials reported positive results vs teriflunomide in relapsing multiple sclerosis.1 "I'd say this is probably one of several more indications to come in the life of remibrutinib," Chovatiya said.7

Who manufactures remibrutinib, and what is the brand name?

Remibrutinib is manufactured by Novartis and marketed as Rhapsido.1,2

References

1. Novartis. Novartis Rhapsido (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). Published October 7, 2026. Accessed October 7, 2026. https://www.novartis.com/us-en/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu

2. Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp; 2026. Accessed October 7, 2026. https://www.novartis.com/us-en/sites/novartis_us/files/rhapsido.pdf

3. HCPLive. Trial data and safety of remibrutinib for CSU. https://www.hcplive.com/view/trial-data-and-safety-of-remibrutinib-for-csu. Published July 15, 2026. Accessed October 7, 2026.

4. Novartis. Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral targeted BTKi treatment for chronic spontaneous urticaria (CSU). Published September 30, 2025. Accessed October 11, 2026. https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu

5. Johnson V. Remibrutinib receives FDA approval for symptomatic dermographism. HCPLive. Published October 7, 2026. Accessed October 11, 2026. https://www.hcplive.com/view/remibrutinib-receives-fda-approval-symptomatic-dermographism

6. Remibrutinib and the first on-label option for symptomatic dermographism, with David Cotter, MD, PhD. HCPLive. Published October 16, 2026. https://www.hcplive.com/view/remibrutinib-first-on-label-option-symptomatic-dermographism-david-cotter

7. Chovatiya R. Atopic dermatitis pipeline and remibrutinib approval for dermographism. HCPLive. Published October 11, 2026. https://www.hcplive.com/view/atopic-dermatitis-pipeline-remibrutinib-approval-dermographism